XRAY · XBRL financial data

DENTSPLY SIRONA financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (XRAY's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	947	1,012*	953	984	951	905*	879	936	904	961*	880	898
Cost of goods and services sold	452	490*	447	473	456	459*	413	446	463	518*	453	405
Gross profit	495	522*	506	511	495	446*	466	490	441	443*	427	493
Research and development	46	43*	42	41	40	42*	36	37	37	40*	44	45
Selling, general and administrative	372	409*	415	399	390	401*	358	342	355	383*	351	364
Operating income (loss)	(236)	73*	42	50	(462)	(509)*	63	(128)	(218)	(139)*	(35)	82
Interest expense	18	23*	18	17	18	16*	19	24	23	22*	24	22
Other income (expense)	4	7*	7	1	2	2*	0	(1)	11	14*	17	12
Income tax expense (benefit)	16	(15)*	14	38	17	(95)*	25	(109)	198	(2)*	(32)	36
Net income (loss)	(266)	67*	18	(4)	(494)	(430)*	20	(45)	(427)	(146)*	(10)	37
Earnings per share, basic USD per share	(1.25)	0.32*	0.09	(0.02)	(2.46)	(2.16)*	0.10	(0.22)	(2.14)	(0.73)*	(0.05)	0.18
Earnings per share, diluted USD per share	(1.25)	0.32*	0.09	(0.02)	(2.46)	(2.17)*	0.10	(0.22)	(2.14)	(0.73)*	(0.05)	0.18
Weighted average shares, basic millions of shares	212	210*	207	206	201	199*	199	199	200	200*	200	200
Weighted average shares, diluted millions of shares	212	209*	209	206	201	198*	200	199	200	199*	200	201

Balance sheet

CSV

Fiscal quarters (XRAY's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	309	334	291	279	296	272	398	359	363	326	190	239
Inventory	651	624	613	608	619	564	612	675	686	642	659	665
Prepaid and other current assets	304	320	342	280	335	354	364	286	369	367	374	404
Total current assets	1,913	1,973	1,902	1,758	1,921	1,746	1,978	1,966	2,072	2,023	1,845	1,928
Property and equipment, net	753	800	782	789	817	—	—	—	—	—	—	—
Right-of-use asset	182	178	171	162	150	136	133	139	131	139	139	129
Goodwill	2,374	2,438	2,400	2,389	1,937	1,597	1,632	1,528	1,270	1,148	1,142	1,138
Total assets	7,201	7,370	7,123	6,897	6,626	5,753	6,050	6,069	5,653	5,429	5,229	5,204
Accounts payable	262	305	279	287	297	241	276	268	268	300	259	260
Accrued liabilities	732	749	681	650	798	754	738	672	712	700	688	664
Current portion of long-term debt	—	77	—	—	—	128	—	—	—	228	—	—
Total current liabilities	1,218	1,425	1,330	1,323	1,542	1,589	1,793	1,166	1,405	1,343	1,207	1,185
Long-term debt	1,803	1,796	1,747	1,737	1,795	1,586	1,593	2,218	2,017	2,015	2,006	1,996
Lease liability, non-current	133	125	120	113	103	91	88	92	85	93	95	88
Total liabilities	3,830	4,076	3,865	3,833	4,136	3,810	4,040	4,108	4,175	4,089	3,910	3,853
Retained earnings (accumulated deficit)	167	205	190	152	(374)	(835)	(848)	(925)	(1,385)	(1,564)	(1,574)	(1,537)
Total stockholders' equity	3,375	3,293	3,258	3,064	2,491	1,942	2,010	1,960	1,478	1,339	1,318	1,351
Total liabilities and equity	7,201	7,370	7,123	6,897	6,626	5,753	6,050	6,069	5,653	5,429	5,229	5,204
Common shares outstanding (cover page) millions of shares	212	207	208	203	199	199	199	199	200	200	200	199

Cash flows

CSV

Fiscal quarters (XRAY's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(266)	67*	18	(4)	(494)	(430)*	20	(45)	(427)	(146)*	(10)	37
Stock-based compensation	2*	13*	11	12*	12*	4*	10	9*	6*	8*	8	9*
Depreciation and amortization	—	year only	86	86	89	88*	79	88	92	93*	79	85
Net cash from operating activities	134*	160*	25	208*	141*	87*	7	48*	79*	101*	40	99*
Net cash from investing activities	(2)*	(20)*	(43)	(50)*	(47)*	(57)*	(17)	(34)*	(36)*	(45)*	(53)	(39)*
Share repurchases	0*	150*	0	150*	100*	0*	—	—	0*	0*	—	—
Dividends paid	29*	30*	29	33*	33*	31*	32	32*	32*	32*	32	0*
Proceeds from long-term debt	2*	(2)*	—	—	0*	1*	—	—	1*	2*	—	—
Repayments of long-term debt	5*	1*	3	3*	2*	80*	2	0*	1*	144*	31	0*
Net cash from financing activities	(109)*	(128)*	(14)	(171)*	(79)*	(38)*	123	(68)*	(36)*	(99)*	(119)	(11)*
Net change in cash	14*	25*	(43)	(12)*	17*	(24)*	126	(39)*	4*	(37)*	(136)	49*

Compare with peers

SIC 3843 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3843 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Dentsply Sirona	239	898	99*	199.4M	—	Q2 FY26 10-QJun 30, 2026
PROCEPT BioRobotics	228	94	(19)*	57.3M	11.8 quarters	Q2 FY26 10-QJun 30, 2026
Icu Medical	298	552	80*	25.0M	—	Q2 FY26 10-QJun 30, 2026
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026
Inspire Medical Systems	191	207	46*	29.0M	—	Q3 FY26 10-QSep 30, 2026
Masimo	125	404	45	52.4M	—	Q1 FY26 10-QApr 4, 2026
Envista Holdings	1,126	731	119*	160.6M	—	Q2 FY26 10-QJul 3, 2026
LivaNova	517	391	67*	55.1M	—	Q2 FY26 10-QJun 30, 2026
Integer Holdings	14	450	37*	34.0M	—	Q3 FY26 10-QOct 2, 2026

Not investment advice. Not affiliated with the U.S. SEC.